References
- Burckhardt G. (2012). Drug transport by organic anion transporters (OATs). Pharmacol Ther 136:106–30
- Carroll MD, Kit BK, Lacher DA, Yoon SS. (2013). Total and high-density lipoprotein cholesterol in adults: National Health and Nutrition Examination Survey, 2011–2012. NCHS data brief, 1–8
- Chisaki I, Kobayashi M, Itagaki S, et al. (2009). Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver. Biochim Biophys Acta 1788:2396–403
- DeGorter MK, Xia CQ, Yang JJ, Kim RB. (2012). Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 52:249–73
- Ghose R, Omoluabi O, Gandhi A, et al. (2011). Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci 89:57–64
- Jedlitschky G, Hoffmann U, Kroemer HK. (2006). Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol 2:351–66
- Jigorel E, Le Vee M, Boursier-Neyret C, et al. (2006). Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 34:1756–63
- Kast HR, Goodwin B, Tarr PT, et al. (2002). Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277:2908–15
- Khot UN, Khot MB, Bajzer CT, et al. (2003). Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290:898–904
- Kosaka K, Watanabe T, Susukida T, et al. (2015). Key determinants of the circulatory exposure of organic anions: differences in hepatic uptake between multidrug resistance-associated protein 2 (Mrp2)-deficient rats and wild-type rats. Xenobiotica 45:556–62
- Marquez B, Van Bambeke F. (2011). ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug–drug interactions. Curr Drug Targets 12:600–20
- Nigam SK. (2015). What do drug transporters really do? Nature reviews. Drug Discov 14:29–44
- Nowicki MT, Aleksunes LM, Sawant SP, et al. (2008). Renal and hepatic transporter expression in type 2 diabetic rats. Drug Metab Lett 2:11–17
- Paulusma CC, Oude Elferink RP. (1997). The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J Mol Med (Berlin, Germany) 75:420–8
- Pu Q-H, He J-L, Wu M-J, et al. (2015). iTRAQ-based proteomic analysis of tetramethylpyrazine inhibition on lipopolysaccharide-induced microglial activation. Life Sci 121:46–56
- Rizwan AN, Burckhardt G. (2007). Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 24:450–70
- Rodrigues AC, Hirata MH, Hirata RD. (2009). Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs. Pharmacogenomics 10:1007–16
- Sato M, Mamada H, Anzai N, et al. (2010). Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLC22A7) in human. Biol Pharm Bull 33:498–503
- Sheweita SA. (2000). Drug-metabolizing enzymes: mechanisms and functions. Curr Drug Metab 1:107–32
- Wagner M, Halilbasic E, Marschall HU, et al. (2005). CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology (Baltimore, Md.) 42:420–30
- Zhou Y, Zhang GQ, Wei YH, et al. (2013). The impact of drug transporters on adverse drug reaction. Eur J Drug Metab Pharmacokinet 38:77–85